Share chart Outlook Therapeutics, Inc.
Extended chart
Simple chart
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., биофармацевтическая компания, находящаяся на поздней клинической стадии, занимается разработкой и коммерциализацией моноклональных антител для различных офтальмологических показаний. Его ведущим продуктом-кандидатом является ONS-5010, офтальмологический препарат-кандидат бевацизумаба, который находится в фазе III клинических испытаний для лечения влажной возрастной дегенерации желтого пятна и других заболеваний сетчатки. Outlook Therapeutics, Inc. имеет соглашения о сотрудничестве и лицензионные соглашения с IPCA Laboratories Limited; Laboratorios Liomont, S.A. more details| IPO date | 2016-05-13 |
|---|---|
| ISIN | US69012T2069 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.outlooktherapeutics.com |
| Цена ао | 1.29 |
| Change price per day: | 0% (1.29) |
|---|---|
| Change price per week: | -12.84% (1.48) |
| Change price per month: | -12.84% (1.48) |
| Change price per 3 month: | -24.12% (1.7) |
| Change price per half year: | -76.8% (5.56) |
| Change price per year: | -89.2% (11.94) |
| Change price per 3 year: | -35.18% (1.99) |
| Change price per 5 year: | +72% (0.75) |
| Change price per year to date: | -7.86% (1.4) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| iShares Micro-Cap ETF | 0.023 | -13.97 | 1.54048 |
iShares Russell 2000 Growth ETF
|
0.00398 | 38.04 | 0.6026 |
| iShares Russell 3000 ETF | 0.00013 | 0.0303 | 1.43482 |
| 0.01 | 8.03 | 1.19 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Ralph H. Thurman | Independent Executive Chairman | 207.5k | 1949 (76 years) |
| Mr. C. Russell Trenary III | President, CEO & Director | 610.9k | 1958 (67 years) |
| Mr. Lawrence A. Kenyon CPA | Executive VP, CFO, Treasurer, Company Secretary & Director | N/A | 1966 (59 years) |
| Mr. Jeffrey Evanson | Chief Commercial Officer | 451.17k | 1969 (56 years) |
| Mr. Joel Prieve | Senior Vice President of Licensing and M&A | N/A | |
| Dr. Surendra Sharma M.D. | Senior Vice President of Medical Affairs | N/A | |
| Dr. Jennifer M. Kissner Ph.D. | Senior Vice President of Clinical Development & Regulatory Affairs | N/A | |
| Mr. Jedd Comiskey | Senior VP - Head of Europe | N/A |
Address: United States, Iselin. NJ, Building F - open in Google maps, open in Yandex maps
Website: https://www.outlooktherapeutics.com
Website: https://www.outlooktherapeutics.com
